Positive patent notice for Phal-501

PharmaLundensis has now received a review report from the PCT authority regarding the company’s mercury-binding substance Phal-501. The report is positive and states that the PCT application meets all the requirements for patenting (novelty, inventive step and industrial applicability). The PCT application can now form the basis for patents in a large number of countries in the world that are part of the PCT cooperation, which are most major industrial nations.

CEO Staffan Skogvall: “The PCT review confirms that our substances are novel and patentable, which opens up the possibility of large revenues. When clinical studies confirm a good effect on COPD/chronic bronchitis and some other diseases, Phal-501 will have a very high value.”